Neoadjuvant therapy with weekly docetaxel and cisplatin, 5-fluorouracil continuous infusion, and concurrent radiotherapy in patients with locally advanced esophageal cancer produced a high percentage of long-lasting pathological complete response: A phase 2 study

Cancer

Volumn 119, Issue 5, 2013, Pages 939-945

  Pasini, Felice ^a   De Manzoni, Giovanni ^b   Zanoni, Andrea ^b   Grandinetti, Antonio ^c   Capirci, Carlo ^d   Pavarana, Michele ^c   Tomezzoli, Anna ^c   Rubello, Domenico ^d   Cordiano, Claudio ^b  

^a Ospedale S Maria della Misericordia   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c UNIVERSITY HOSPITAL OF VERONA   (Italy)

^d Ospedale Civile di Rovigo   (Italy)

Author keywords

chemoradiotherapy; docetaxel; esophageal cancer; weekly chemotherapy

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROURACIL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASTHENIA; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DIARRHEA; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGITIS; ESOPHAGOSCOPY; ESOPHAGUS BIOPSY; ESOPHAGUS CANCER; FEMALE; GASTROSCOPY; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIMARY TUMOR; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; TAXOIDS;

EID: 84874259578     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27822     Document Type: Article

References (45)

1. Geh JI, Crellin AM, Glynne-Jones R,. Preoperative (neoadjuvant) chemoradiotherapy in oesophageal cancer. Br J Surg. 2001; 88: 338-356.
2. Urschel JD, Vasan H,. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg. 2003; 185: 538-543.
3. Fiorica F, Di Bona D, Schepis F, et al. Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and metaanalysis. Gut. 2004; 53: 925-930.
4. Gebski V, Burmeister B, Smithers BM, et al. Australasian Gastro-Intestinal Trials Group. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol. 2007; 8: 226-234.
5. Sjoquist KM, Burmeister BH, Smithers BM, et al. Australasian Gastro-Intestinal Trials Group. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011; 12: 681-692.
6. Courrech Staal EF, Aleman BM, Boot H, van Velthuysen ML, van Tinteren H, van Sandick JW,. Systematic review of the benefits and risks of neoadjuvant chemoradiation for oesophageal cancer. Br J Surg. 2010; 97: 1482-1496.
7. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP,. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996; 335: 462-467.
8. Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008; 26: 1086-1092.
9. Cao XF, He XT, Ji L, Xiao J, Lv J,. Effects of neoadjuvant radiochemotherapy on pathological staging and prognosis for locally advanced esophageal squamous cell carcinoma. Dis Esophagus. 2009; 22: 477-481.
10. van Hagen P, Hulshof MC, van Lanschot JJ, et al. CROSS Group. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012; 366: 2074-2084.
11. Bosset JF, Gignoux M, Triboulet JP, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagous. N Engl J Med. 1997; 337: 161-167.
12. Burmeister BH, Smithers BM, Gebski V, et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol. 2005; 6: 659-668.
13. Berger AC, Farma J, Scott WJ, et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol. 2005; 23: 4330-4337.
14. Chirieac LR, Swisher SG, Ajani JA, et al. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer. 2005; 103: 1347-1355.
15. Hammoud ZT, Kesler KA, Ferguson MK, et al. Survival outcomes of resected patients who demonstrate a pathologic complete response after neoadjuvant chemoradiation therapy for locally advanced esophageal cancer. Dis Esophagus. 2006; 19: 69-72.
16. Rohatgi PR, Swisher SG, Correa AM, et al. Histologic subtypes as determinants of outcome in esophageal carcinoma patients with pathologic complete response after preoperative chemoradiotherapy. Cancer. 2006; 106: 552-558.
17. Donahue JM, Nichols FC, Li Z, Schomas DA, et al. Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enhanced survival. Ann Thorac Surg. 2009; 87: 392-398.
18. Mason KA, Hunter NR, Milas M, et al. Docetaxel enhances tumor radioresponse in vivo. Clin Cancer Res. 1997; 3: 2431-2438.
19. Pasini F, de Manzoni G, Pedrazzani C, et al. High pathological response rate in locally advanced esophageal cancer after neoadjuvant combined modality therapy: dose finding of a weekly chemotherapy schedule with protracted venous infusion of 5-fluorouracil and dose escalation of cisplatin, docetaxel and concurrent radiotherapy. Ann Oncol. 2005; 16: 1133-1139.
20. Rizk NP, Venkatraman E, Bains MS, et al. American Joint Committee on Cancer. American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma. J Clin Oncol. 2007; 25: 507-512.
21. Meluch AA, Greco A, Gray JR, et al. Preoperative therapy with concurrent paclitaxel/carboplatin/infusional 5-FU and radiation therapy in locoregional esophageal cancer: final results of a Minnie Pearl Cancer Research Network phase II trial. Cancer J. 2003; 9: 251-260.
22. Roof KS, Coen J, Lynch TJ, et al. Concurrent cisplatin, 5-FU, paclitaxel, and radiation therapy in patients with locally advanced esophageal cancer. Int J Radiat Oncol Biol Phys. 2006; 65: 1120-1128.
23. Kim DW, Blanke CD, Wu H, et al. Phase II study of preoperative paclitaxel/cisplatin with radiotherapy in locally advanced esophageal cancer. Int J Radiat Oncol Biol Phys. 2007; 67: 397-404.
24. Jatoi A, Martenson JA, Foster NR, et al. Paclitaxel, carboplatin, 5-fluorouracil, and radiation for locally advanced esophageal cancer: phase II results of preliminary pharmacologic and molecular efforts to mitigate toxicity and predict outcomes: North Central Cancer Treatment Group (N0044). Am J Clin Oncol. 2007; 30: 507-513.
25. Kelsey CR, Chino JP, Willett CG, et al. Paclitaxel-based chemoradiotherapy in the treatment of patients with operable esophageal cancer. Int J Radiat Oncol Biol Phys. 2007; 69: 770-776.
26. van de Schoot L, Romme EA, van der Sangen MJ, et al. A highly active and tolerable neoadjuvant regimen combining paclitaxel, carboplatin, 5-FU, and radiation therapy in patients with stage II and III esophageal cancer. Ann Surg Oncol. 2008; 15: 88-95.
27. Luu TD, Gaur P, Force SD, et al. Neoadjuvant chemoradiation versus chemotherapy for patients undergoing esophagectomy for esophageal cancer. Ann Thorac Surg. 2008; 85: 1217-1224.
28. van Meerten E, Muller K, Tilanus HW, et al. Neoadjuvant concurrent chemoradiation with weekly paclitaxel and carboplatin for patients with oesophageal cancer: a phase II study. Br J Cancer. 2006; 94: 1389-1394.
29. Lin CC, Hsu CH, Cheng JC, et al. Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer. Ann Oncol. 2007; 18: 93-98.
30. Ruhstaller T, Widmer L, Schuller JC, et al. Swiss Group for Clinical Cancer Research. Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02). Ann Oncol. 2009; 20: 1522-1528.
31. Orditura M, Galizia G, Napolitano V, et al. Weekly chemotherapy with cisplatin and paclitaxel and concurrent radiation therapy as preoperative treatment in locally advanced esophageal cancer: a phase II study. Cancer Invest. 2010; 28: 820-827.
32. Spigel DR, Greco FA, Meluch AA, et al. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction. J Clin Oncol. 2010; 28: 2213-2219.
33. Ruhstaller T, Pless M, Dietrich D, et al. Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II trial (SAKK 75/06). J Clin Oncol. 2011; 29: 626-631.
34. Adelstein DJ, Rice TW, Rybicki LA, et al. Does paclitaxel improve the chemoradiotherapy of locoregionally advanced esophageal cancer? A nonrandomized comparison with fluorouracil-based therapy. J Clin Oncol. 2000; 18: 2032-2039.
35. Stahl M, Walz MK, Stuschke M, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 2009; 27: 851-856.
36. Ajani JA, Winter K, Komaki R, et al. Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113. J Clin Oncol. 2008; 26: 4551-4556.
37. Adenis A, Conroy T,. Fluorouracil should continue to be incorporated in the treatment of localized esophageal cancer. J Clin Oncol. 2009; 27: 467-468.
38. Wada Y, Yoshida K, Suzuki T, et al. Synergistic effects of docetaxel and S-1 by modulating the expression of metabolic enzymes of 5-fluorouracil in human gastric cancer cell lines. Int J Cancer. 2006; 119: 783-791.
39. Tamatani T, Ferdous T, Takamaru N, et al. Antitumor efficacy of sequential treatment with docetaxel and 5-fluorouracil against human oral cancer cells. Int J Oncol. 2012; 41: 1148-1156.
40. Maeda S, Sugiura T, Saikawa Y, et al. Docetaxel enhances the cytotoxicity of cisplatin to gastric cancer cells by modification of intracellular platinum metabolism. Cancer Sci. 2004; 95: 679-684.
41. Balcer-Kubiczek EK, Attarpour M, Jiang J, Kennedy AS, Suntharalingam M,. Cytotoxicity of docetaxel (Taxotere) used as a single agent and in combination with radiation in human gastric, cervical and pancreatic cancer cells. Chemotherapy. 2006; 52: 231-240.
42. Maeda S, Saikawa Y, Kubota T, et al. No cross-resistance of taxotere and taxol to conventional chemotherapeutic agents against gastric cancers as detected by MTT assay. Anticancer Res. 2003; 23: 3147-3150.
43. Ajani JA, Correa AM, Swisher SG, Wu TT,. For localized gastroesophageal cancer, you give chemoradiation before surgery, but then what happens? J Clin Oncol. 2007; 25: 4315-4316.
44. Chuang SC, Hashibe M, Scelo G, et al. Risk of second primary cancer among esophageal cancer patients: a pooled analysis of 13 cancer registries. Cancer Epidemiol Biomarkers Prev. 2008; 17: 1543-1549.
45. Levi F, Randimbison L, Maspoli M, Te VC, La Vecchia C,. Second neoplasms after oesophageal cancer. Int J Cancer. 2007; 121: 694-697.